Sensei Biotherapeutics, Inc.
SNSE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | -$5 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | -$5 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | -0% | – | – | – |
| R&D Expenses | $3 | $3 | $4 | $4 |
| G&A Expenses | $2 | $0 | $0 | $0 |
| SG&A Expenses | $2 | $3 | $4 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5 | $5 | $7 | $7 |
| Operating Income | -$5 | -$5 | -$7 | -$7 |
| % Margin | 100% | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$5 | -$5 | -$7 | -$8 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$5 | -$7 | -$8 |
| % Margin | 94.2% | – | – | – |
| EPS | -3.62 | -3.91 | -0.27 | -0.31 |
| % Growth | 7.4% | -1,348.1% | 12.9% | – |
| EPS Diluted | -3.62 | -3.91 | -0.27 | -0.31 |
| Weighted Avg Shares Out | 1 | 1 | 25 | 25 |
| Weighted Avg Shares Out Dil | 1 | 1 | 25 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$5 | -$7 | -$8 |
| % Margin | 93.4% | – | – | – |